PHH Investments Ltd. raised its position in Johnson & Johnson (NYSE:JNJ) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,211 shares of the company’s stock after acquiring an additional 1,116 shares during the period. Johnson & Johnson comprises approximately 0.8% of PHH Investments Ltd.’s holdings, making the stock its 12th largest holding. PHH Investments Ltd.’s holdings in Johnson & Johnson were worth $2,368,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Eagle Ridge Investment Management raised its holdings in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Eagle Ridge Investment Management now owns 27,522 shares of the company’s stock worth $3,578,000 after buying an additional 928 shares in the last quarter. Oliver Luxxe Assets LLC raised its holdings in shares of Johnson & Johnson by 12.7% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock worth $2,320,000 after buying an additional 1,972 shares in the last quarter. Progressive Investment Management Corp grew its position in Johnson & Johnson by 6.8% during the 3rd quarter. Progressive Investment Management Corp now owns 40,317 shares of the company’s stock worth $5,242,000 after acquiring an additional 2,584 shares during the last quarter. Middleton & Co Inc MA grew its position in Johnson & Johnson by 40.5% during the 3rd quarter. Middleton & Co Inc MA now owns 39,272 shares of the company’s stock worth $5,106,000 after acquiring an additional 11,315 shares during the last quarter. Finally, Sitrin Capital Management LLC grew its position in Johnson & Johnson by 1.6% during the 2nd quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock worth $6,480,000 after acquiring an additional 792 shares during the last quarter. 67.35% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE JNJ) opened at $134.35 on Wednesday. The company has a market capitalization of $360,450.00, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.88%.
A number of research firms recently commented on JNJ. Citigroup decreased their price target on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 27th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target on the stock in a research report on Thursday, January 11th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Jefferies Group set a $165.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, February 26th. Finally, Stifel Nicolaus increased their price target on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $146.26.
In other news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: “PHH Investments Ltd. Purchases 1,116 Shares of Johnson & Johnson (JNJ)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/14/phh-investments-ltd-purchases-1116-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.